Author: OurCrowd

[Appdome in PR Newswire] Global Mobile App Survey: Consumers want better fraud protections and app maker accountability to ensure safe experiences

Dec 14, 2023 |

REDWOOD CITY, Calif., Dec. 14, 2023 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile app defense, today announced the results of its new 2023 Global Consumer Expectations of Mobile App Security study. The report features detailed data and responses from 25,000 consumers who provided insights about their mobile app usage, as well as their expectations and desires around mobile app security and protection against fraud, malware and other mobile threats. Read...

Read More

[Ursa Major in Manifest Space with Morgan Brennan] $138M round raise with Ursa Major CEO Joe Laurienti

Dec 14, 2023 |

Venture capital is creeping back into the space sector, with Ursa Major raising $138 million in Series D and D-1 rounds. Capital from the likes of RTX Ventures, BlackRock, Explorer 1 Fund & more will help the rocket propulsion startup to produce engines for rocket launches, hypersonic vehicles – and enable expansion into a new defense-focused market. Founder & CEO Joe Laurienti joins Morgan Brennan to discuss defense tech, the case for 3-D printed rocket engines, and more from the Reagan National Defense Forum. Listen...

Read More

[IQM in PR Newswire] IQM announces expansion to US, signs partnership with UC Berkeley to develop advanced quantum processors

Dec 14, 2023 |

ESPOO, Finland, Dec. 14, 2023 /PRNewswire/ — IQM Quantum Computers (IQM), a global leader in building quantum computers, today announced its expansion into the United States market and signed a strategic partnership with the University of California, Berkeley, in Quantum Information Science (QIS) through the development and operation of the next generation of advanced superconducting quantum processors. Read...

Read More

[Biolojic in Business Wire] Teva and Biolojic Design announce exclusive license agreement for the development of a therapeutic antibody for Atopic Dermatitis and Asthma

Dec 14, 2023 |

TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. Read...

Read More